207 related articles for article (PubMed ID: 15379638)
1. Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor: rationale for their use in clinical cardiology.
Rossi ML; Zavalloni D
Mini Rev Med Chem; 2004 Sep; 4(7):703-9. PubMed ID: 15379638
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
3. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
4. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
[TBL] [Abstract][Full Text] [Related]
5. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
Vorchheimer DA; Badimon JJ; Fuster V
JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
[TBL] [Abstract][Full Text] [Related]
6. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
Schneider DJ; Taatjes DJ; Sobel BE
Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
Matzdorff A; Voss R
Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
[TBL] [Abstract][Full Text] [Related]
9. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
[TBL] [Abstract][Full Text] [Related]
10. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization.
Furman MI; Krueger LA; Linden MD; Barnard MR; Frelinger AL; Michelson AD
J Am Coll Cardiol; 2004 Jun; 43(12):2319-25. PubMed ID: 15193700
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein IIb/IIIa receptor antagonists in the management of cardiovascular diseases.
Chong PH
Am J Health Syst Pharm; 1998 Nov; 55(22):2363-86. PubMed ID: 9825033
[TBL] [Abstract][Full Text] [Related]
12. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Bhatt DL; Topol EJ
JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
[TBL] [Abstract][Full Text] [Related]
13. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development.
Verstraete M
Circulation; 2000 Feb; 101(6):E76-80. PubMed ID: 10673265
[TBL] [Abstract][Full Text] [Related]
14. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
Ilveskero S; Lassila R
Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
[TBL] [Abstract][Full Text] [Related]
16. IIb's are not IIb's.
Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
Keating FK; Whitaker DA; Sobel BE; Schneider DJ
Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
[TBL] [Abstract][Full Text] [Related]
18. The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anticoagulants used.
Aalto-Setälä K; Karhunen PJ; Mikkelsson J; Niemelä K
J Thromb Thrombolysis; 2005 Aug; 20(1):57-63. PubMed ID: 16133898
[TBL] [Abstract][Full Text] [Related]
19. Progress in the field of GPIIb/IIIa antagonists.
Hanson J; de Leval X; David JL; Supuran C; Pirotte B; Dogné JM
Curr Med Chem Cardiovasc Hematol Agents; 2004 Apr; 2(2):157-67. PubMed ID: 15320798
[TBL] [Abstract][Full Text] [Related]
20. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
Mascelli MA; Worley S; Veriabo NJ; Lance ET; Mack S; Schaible T; Weisman HF; Jordan RE
Circulation; 1997 Dec; 96(11):3860-6. PubMed ID: 9403608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
